Core Viewpoint - The company has initiated clinical trials for its oral small molecule GLP-1 receptor agonist ASC30, targeting type 2 diabetes and obesity, with significant data expected by Q3 2026 [1][3]. Group 1: Clinical Trials and Results - The company announced the completion of the first dosing of ASC30 in a 13-week Phase II study for type 2 diabetes in the U.S., with top-line data anticipated in Q3 2026 [1]. - A recent 13-week Phase II study for ASC30 in treating obesity involved 125 participants, showing statistically significant and clinically meaningful weight loss of 5.4%, 7.0%, and 7.7% for daily doses of 20 mg, 40 mg, and 60 mg respectively [2]. - The overall discontinuation rate due to adverse events in the obesity study was reported at 4.8%, indicating a favorable safety profile [2]. Group 2: Strategic Implications - The expansion of ASC30's clinical development into the diabetes treatment market is viewed as a logical strategic move, providing an opportunity to establish ASC30 as a best-in-class oral therapy option for patients [3].
歌礼制药-B(01672)宣布口服小分子GLP-1R激动剂ASC30治疗糖尿病的13周美国II期研究完成首批受试者给药